Pharmaceutical Technology Editors

Fresenius Kabi recalls chemotherapy drug because of possible glass particulate within the drug vials.

Metabolic-disease biotech Amicus Therapeutics announced a manufacturing agreement with Catalent’s Paragon Gene Therapy unit for gene therapy manufacturing.

The guidance document provides recommendations for developing content for Instructions-for-Use documents for human prescription drugs, biological products, and drug-device or biologic-device combination products.

FDA sent warning letters detailing violations of current good manufacturing practices to three companies that repack APIs.

CHMP of the European Medicines Agency has recommended a change to the European marketing authorization for AstraZeneca’s Forxiga (dapagliflozin) in patients with Type-2 diabetes.

The Bittium Wearable Platform with Philips EmoGraphy & CardioSense solution has been unveiled as one of five winners of GSK’s “Transform the Future of Self-Care” innovation content.

Cegedim has announced the launch of its Health Data Business in support of pharmaceutical companies, clinical research organizations, and academic institutions.

AstraZeneca has revealed that the CHMP of the European Medicines Agency has given a positive opinion to adding a self-administration option for Fasenra (benralizumab).

German-based company, Velabs Therapeutics, has closed its Series B financing round, raising EUR3 million (US$3.4 million).

New figures published by the ABPI have revealed the continuation of significant investment by the pharmaceutical industry into R&D in the United Kingdom.

Amicus Therapeutics has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific.

Pfizer has successfully completed its acquisition of Therachon, a privately held clinical-stage biotechnology company.

Fujifilm Irvine Scientific has announced plans to open a third manufacturing facility in Tilburg, The Netherlands.

FDA proposes rule to help ensure availability of hormones and enzymes formerly classified as drugs, and to stimulate biosimilars competition.

Lonza Pharma & Biotech announced a binding contractual commitment for the purchase of a sterile drug product fill and finish facility.

The Galien Foundation has selected nominees for its award, which recognizes those therapies and technologies with the greatest potential impact on human health.

Research from the Institute for Research in Biomedicine offers insight into the source of asymmetry between nucleic acid hybrids.

The companies will join forces to develop new immuno-oncology therapies in a deal worth up to $470 million.

FDA is collecting public comments on a draft guidance for bioanalytical method validation developed by ICH.

FDA approved first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system.

The companies will work to develop a liver tissue model for screening the toxicity of drugs.

More than 30 lots of losartan drug products have been recalled due to contaminated API manufactured by Hetero Labs.

Novavax will sell two Maryland-based vaccine development and manufacturing facilities for Catalent’s expanding gene therapy footprint.

CHMP has recommended that the indication of Victoza (liraglutide) be extended to include its use in pediatric patients with Type 2 diabetes.

ABPI and BIA have issued responses to the recently published governmental guidance on European Union exit preparedness.

The Gyrolab E. coli HCP Kit quantifies host cell protein impurities from Escherichia coli expression systems used in biotherapeutic production.

Three months following his departure from FDA, former commissioner Scott Gottlieb joins Pfizer’s board of directors.

Cytek Biosciences’ Cytek Aurora advanced flow cytometry system uses five lasers to enable seeing more than 30 colors from a single sample.

SCIEX added new innovations to improve laboratory workflows and data acquisition from samples.

The new flow cytometer system boasts enhanced sensitivity and user-friendly features.